Sutro Biopharma (STRO) Revenue & Revenue Breakdown
Sutro Biopharma Revenue Highlights
Latest Revenue (Y)
$153.73M
Latest Revenue (Q)
$25.71M
Main Segment (Y)
Collaboration Revenue
Main Geography (Y)
Collaboration Revenue
Sutro Biopharma Revenue by Period
Sutro Biopharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $153.73M | 126.84% |
| 2022-12-31 | $67.77M | 9.52% |
| 2021-12-31 | $61.88M | 44.84% |
| 2020-12-31 | $42.72M | -0.03% |
| 2019-12-31 | $42.74M | 11.24% |
| 2018-12-31 | $38.42M | -25.75% |
| 2017-12-31 | $51.74M | -13.38% |
| 2016-12-31 | $59.73M | - |
Sutro Biopharma generated $153.73M in revenue during NA 2023, up 126.84% compared to the previous quarter, and up 400.14% compared to the same period a year ago.
Sutro Biopharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $25.71M | 97.62% |
| 2024-03-31 | $13.01M | -88.56% |
| 2023-12-31 | $113.72M | 571.95% |
| 2023-09-30 | $16.92M | 62.54% |
| 2023-06-30 | $10.41M | -17.85% |
| 2023-03-31 | $12.67M | 46.83% |
| 2022-12-31 | $8.63M | -65.67% |
| 2022-09-30 | $25.15M | -10.50% |
| 2022-06-30 | $28.10M | 376.45% |
| 2022-03-31 | $5.90M | -44.65% |
| 2021-12-31 | $10.65M | 25.09% |
| 2021-09-30 | $8.52M | -69.64% |
| 2021-06-30 | $28.05M | 91.33% |
| 2021-03-31 | $14.66M | 77.10% |
| 2020-12-31 | $8.28M | -53.55% |
| 2020-09-30 | $17.82M | 88.22% |
| 2020-06-30 | $9.47M | 32.40% |
| 2020-03-31 | $7.15M | -36.74% |
| 2019-12-31 | $11.30M | -7.92% |
| 2019-09-30 | $12.28M | 16.65% |
| 2019-06-30 | $10.53M | 21.97% |
| 2019-03-31 | $8.63M | -54.79% |
| 2018-12-31 | $19.09M | 143.57% |
| 2018-09-30 | $7.84M | 37.38% |
| 2018-06-30 | $5.70M | -1.54% |
| 2018-03-31 | $5.79M | 43.39% |
| 2017-12-31 | $4.04M | -76.91% |
| 2017-09-30 | $17.50M | 15.88% |
| 2017-06-30 | $15.10M | - |
| 2017-03-31 | $15.10M | - |
Sutro Biopharma generated $25.71M in revenue during Q2 2024, up 97.62% compared to the previous quarter, and up 202.82% compared to the same period a year ago.
Sutro Biopharma Revenue Breakdown
Sutro Biopharma Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 18 |
|---|---|
| Other Revenue | $5.42M |
| Collaboration Revenue | $13.54M |
Sutro Biopharma's latest annual revenue breakdown by segment (product or service), as of Dec 18: Collaboration Revenue (71.40%), and Other Revenue (28.60%).
Quarterly Revenue by Product
| Product/Service | Dec 18 | Sep 18 |
|---|---|---|
| Other Revenue | $654.00K | $912.00K |
| Collaboration Revenue | $18.43M | - |
Sutro Biopharma's latest quarterly revenue breakdown by segment (product or service), as of Dec 18: Collaboration Revenue (96.57%), and Other Revenue (3.43%).
Sutro Biopharma Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 18 |
|---|---|
| Collaboration Revenue | $13.54M |
| Other Revenue | $5.42M |
Sutro Biopharma's latest annual revenue breakdown by geography, as of Dec 18: Collaboration Revenue (71.40%), and Other Revenue (28.60%).
Quarterly Revenue by Country
| Country | Dec 18 | Sep 18 |
|---|---|---|
| Other Revenue | $654.00K | $912.00K |
| Collaboration Revenue | $18.43M | - |
Sutro Biopharma's latest quarterly revenue breakdown by geography, as of Dec 18: Collaboration Revenue (96.57%), and Other Revenue (3.43%).
Sutro Biopharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| STRO | Sutro Biopharma | $153.73M | $25.71M |
| MRUS | Merus | $43.95M | $11.77M |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| ANAB | AnaptysBio | $17.16M | $30.02M |
| MGTX | MeiraGTx | $14.02M | $10.91M |
| CNTA | Centessa Pharmaceuticals | $6.88M | - |
| KROS | Keros Therapeutics | $151.00K | $37.00K |
| OPT | Opthea | $108.41K | $61.27K |
| PCVX | Vaxcyte | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| SNDX | Syndax Pharmaceuticals | - | $12.50M |
| MLYS | Mineralys Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
| HLVX | HilleVax | - | - |
| GNTA | Genenta Science S.p.A. | - | - |